AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders

Summary

RATIONALE: Giving chemotherapy with or without total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer or abnormal cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil before and after transplant may stop this from happening.

PURPOSE: This clinical trial is studying how well four different chemotherapy regimens given with or without total-body irradiation before umbilical cord blood transplant work in treating patients with relapsed or refractory hematologic cancer.

Conditions

• Leukemia
• Lymphoma
• Myelodysplastic Syndromes

Interventions

BIOLOGICAL

filgrastim

DRUG

Busulfan

DRUG

Cyclophosphamide

DRUG

Cyclosporine

DRUG

Fludarabine phosphate

DRUG

Melphalan

DRUG

Mycophenolate Mofetil

PROCEDURE

allogeneic hematopoietic stem cell transplantation

PROCEDURE

umbilical cord blood transplantation

RADIATION

total-body irradiation

RADIATION

Fractionated total body irradiation

Sponsors & Collaborators

• National Cancer Institute (NCI)

  collaborator NIH

• City of Hope Medical Center

  lead OTHER

Principal Investigators

• Anna Pawlowska, MD · City of Hope Medical Center

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

0 Years

Max Age

120 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2005-08-16

Primary Completion

2009-11-11

Completion

2024-05-28

Countries

• United States

Study Locations